Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 445

Sort by

Sort Order Select

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Atypical intrasinusoidal bone marrow involvement by hairy cell leukemia

Giovanni Martino, Stefano Ascani

Blood (2020) 135 (5): 392.

https://doi.org/10.1182/blood.2019003833

Published: 2020

Journal Articles

Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes

Nanditha Mallesh, Max Zhao, Franz Elsner, PhD, Hannes Lueling, PhD, Richard Schabath, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD, Peter Krawitz, MD, Wolfgang Kern, MD

Blood (2019) 134 (Supplement_1): 2094.

https://doi.org/10.1182/blood-2019-130483

Published: 2019

Journal Articles

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

Eri Kawata, MD PhD, Anargyros Xenocostas, MD FRCPC, Cyrus C. Hsia, MDBSc,FRCPC, Alejandro Lazo-Langner, MD MSc, Kang Howson-Jan, MD FRCPC, Uday Deotare, MBBS, MD DM, Lalit Saini, MD, Benjamin Hedley, PhD, Ping Yang, PhD DABMGG, Michael Levy, PhD, Hanxin Lin, PhD, Bekim Sadikovic, PhD DABMGG, FACMG, Ian Chin-Yee, MD FRCPC

Blood (2019) 134 (Supplement_1): 3438.

https://doi.org/10.1182/blood-2019-128507

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Rachel Hu, MD, Wei Wei, MS, Kristen Gonter-Aubin, DO, Javier Pinilla Ibarz, MD PhD, Charlene C. Kabel, PharmD, Anthony R. Mato, MDMSCE, Yazan F. Madanat, MD, Sirin Khajavian, MD, Mazyar Shadman, MD, Ashley Hanlon, MD, Danielle M. Brander, MD, Jae H. Park, MD, Martin S. Tallman, MD, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4004.

https://doi.org/10.1182/blood-2019-126381

Published: 2019

Journal Articles

The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna

Alessandro Broccoli, Carolina Terragna, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, MD, Miriam Marangon, Alice Morigi, Laura Nanni, MD, Ginevra Lolli, Matteo Carella, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 4005.

https://doi.org/10.1182/blood-2019-122832

Published: 2019

Journal Articles

Outcome of Atypical Presentations of Hairy Cell Leukemia

Afraa Moustafa, MD, Hawraa M Shwaylia, MD, Mahmood Aldapt, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5267.

https://doi.org/10.1182/blood-2019-121826

Published: 2019

Journal Articles

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

Shi Hui Clarice Choong, MBBS, MRCP, Wee-Joo Chng, MBBS, PhD, Sanjay De Mel, BSc, BM, Te-Chih Liu, FRCPath, MBBS, MRCP, Bei Jenny Li, Li Mei Michelle Poon, Shir Ying Lee, FRCPath,MBBS,MRCP,, Hoon Chung Tae, Rebecca Teng, Seok Wei Stephrene Chan

Blood (2019) 134 (Supplement_1): 5253.

https://doi.org/10.1182/blood-2019-125241

Published: 2019

Journal Articles

Localized Pulmonary Amyloidosis: A Single Institution Experience

Ajay Tambe, MBBS, Poornima Ramadas, MBBS, Mijung Lee, MD, Kanish Mirchia, MD

Blood (2019) 134 (Supplement_1): 5464.

https://doi.org/10.1182/blood-2019-125124

Published: 2019

Journal Articles

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Marcio M Andrade-Campos, MD PhD, Antonio Salar, MD PhD, Blanca Sanchez-Gonzalez, MD, Concepción Fernández-Rodríguez, Eva Gimeno, MD PhD, L Ruiz, Gabriel Piquer, Francesc Garcia-Pallarols, BSc, Natalia Papaleo, MD, Ivonne Vazquez, Lluís Colomo, MD PhD, Beatriz Bellosillo, PhD

Blood (2019) 134 (Supplement_1): 492.

https://doi.org/10.1182/blood-2019-131081

Published: 2019

Journal Articles

Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

Ravi Kumar Alluri, PhD, Nicholas Arce, Philip Klenotic, Chih Chia Su, PhD, Suman Kundu, MBA, Edward Yu, PhD, Renhao Li, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1105.

https://doi.org/10.1182/blood-2019-131386

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

Journal Articles

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Wilson I Gonsalves, MD, Srinivas Devarakonda, MD, Rachid Baz, MD, Natalia Neparidze, MD, Alex A Adjei, MD PhD, Charles Kunos, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3160.

https://doi.org/10.1182/blood-2019-123399

Published: 2019

Journal Articles

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Blood (2019) 134 (Supplement_1): 1527.

https://doi.org/10.1182/blood-2019-126889

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

https://doi.org/10.1182/blood-2019-124515

Published: 2019

NARROW

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Atypical intrasinusoidal bone marrow involvement by hairy cell leukemia

Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes

Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna

Outcome of Atypical Presentations of Hairy Cell Leukemia

Flow Cytometric Immunophenotyping Distinguishes Lymphoplasmacytic Lymphoma from Marginal Zone Lymphoma

Localized Pulmonary Amyloidosis: A Single Institution Experience

Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up

Characterization of Recombinant β2GPI Using Hydrogen-Deuterium Exchange and X-Ray Crystallography

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only